AsiaMedic Limited (SGX:505)
Singapore
· Delayed Price · Currency is SGD 0.0100
-0.0010 (-9.09%)
At close: Mar 27, 2025
AsiaMedic Income Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 28.91 | 23.6 | 18.88 | 18.26 | 15.28 | Upgrade
|
| Other Revenue | 0.17 | 0.15 | 0.16 | 0.17 | 0.1 | Upgrade
|
| Revenue | 29.09 | 23.75 | 19.04 | 18.42 | 15.38 | Upgrade
|
| Revenue Growth (YoY) | 22.46% | 24.72% | 3.38% | 19.81% | -19.31% | Upgrade
|
| Cost of Revenue | 23.28 | 18.4 | 14.78 | 14.25 | 12.88 | Upgrade
|
| Gross Profit | 5.8 | 5.35 | 4.27 | 4.17 | 2.49 | Upgrade
|
| Selling, General & Admin | 0.12 | 0.11 | 0.14 | 0.14 | 0.16 | Upgrade
|
| Other Operating Expenses | 2.56 | 2.45 | 2.15 | 1.97 | 1.81 | Upgrade
|
| Operating Expenses | 5.16 | 4.63 | 3.34 | 3.38 | 4.64 | Upgrade
|
| Operating Income | 0.65 | 0.72 | 0.92 | 0.79 | -2.14 | Upgrade
|
| Interest Expense | -0.57 | -0.42 | -0.24 | -0.15 | -0.2 | Upgrade
|
| Interest & Investment Income | 0.17 | 0.17 | 0.04 | 0.02 | 0.05 | Upgrade
|
| Earnings From Equity Investments | 0.32 | 0.44 | 0.48 | 0.36 | 0.37 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | - | - | 0.09 | -0 | Upgrade
|
| EBT Excluding Unusual Items | 0.57 | 0.91 | 1.21 | 1.12 | -1.92 | Upgrade
|
| Impairment of Goodwill | -0.05 | - | -0.52 | - | - | Upgrade
|
| Asset Writedown | 0.12 | 0.12 | 1.5 | -0.86 | -4.19 | Upgrade
|
| Other Unusual Items | - | - | - | 0.45 | 1.82 | Upgrade
|
| Pretax Income | 0.64 | 1.03 | 2.19 | 0.72 | -4.3 | Upgrade
|
| Income Tax Expense | -0 | -0.89 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | 0.65 | 1.92 | 2.19 | 0.72 | -4.3 | Upgrade
|
| Minority Interest in Earnings | 0.36 | - | - | - | - | Upgrade
|
| Net Income | 1.01 | 1.92 | 2.19 | 0.72 | -4.3 | Upgrade
|
| Net Income to Common | 1.01 | 1.92 | 2.19 | 0.72 | -4.3 | Upgrade
|
| Net Income Growth | -47.44% | -12.13% | 205.72% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 1,155 | 1,132 | 1,120 | 1,120 | 1,094 | Upgrade
|
| Shares Outstanding (Diluted) | 1,155 | 1,132 | 1,120 | 1,120 | 1,094 | Upgrade
|
| Shares Change (YoY) | 1.97% | 1.13% | - | 2.36% | 178.90% | Upgrade
|
| EPS (Basic) | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | Upgrade
|
| EPS (Diluted) | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | Upgrade
|
| EPS Growth | -48.76% | -13.11% | 225.88% | - | - | Upgrade
|
| Free Cash Flow | 0.68 | 0.98 | 0.23 | 3.06 | 1.98 | Upgrade
|
| Free Cash Flow Per Share | 0.00 | 0.00 | - | 0.00 | 0.00 | Upgrade
|
| Gross Margin | 19.95% | 22.52% | 22.40% | 22.65% | 16.23% | Upgrade
|
| Operating Margin | 2.22% | 3.03% | 4.85% | 4.31% | -13.95% | Upgrade
|
| Profit Margin | 3.47% | 8.09% | 11.48% | 3.88% | -27.93% | Upgrade
|
| Free Cash Flow Margin | 2.32% | 4.14% | 1.23% | 16.60% | 12.89% | Upgrade
|
| EBITDA | 1.34 | 1.6 | 1.19 | 1.17 | -0.94 | Upgrade
|
| EBITDA Margin | 4.59% | 6.74% | 6.24% | 6.35% | -6.14% | Upgrade
|
| D&A For EBITDA | 0.69 | 0.88 | 0.27 | 0.38 | 1.2 | Upgrade
|
| EBIT | 0.65 | 0.72 | 0.92 | 0.79 | -2.14 | Upgrade
|
| EBIT Margin | 2.22% | 3.03% | 4.85% | 4.31% | -13.95% | Upgrade
|
Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.